Palisade Bio (NASDAQ:PALI) Price Target Lowered to $8.00 at Maxim Group

Palisade Bio (NASDAQ:PALI) had its price target reduced by Maxim Group from $22.50 to $8.00 in a research report released on Wednesday morning,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Palisade Bio Trading Down 3.8 %

Shares of PALI stock opened at $2.52 on Wednesday. Palisade Bio has a twelve month low of $2.18 and a twelve month high of $22.35. The company has a market capitalization of $3.35 million, a PE ratio of -0.18 and a beta of 1.36. The firm has a fifty day simple moving average of $3.33 and a 200-day simple moving average of $4.18.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.35) by $1.03. Equities research analysts predict that Palisade Bio will post -13.11 EPS for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.